Kimura O, Kurayoshi K, Hoshino K, Sugezawa A, Makino M, Kaibara N
First Department of Surgery, Tottori University School of Medicine, Yonago, Japan.
Surg Today. 1995;25(3):211-6. doi: 10.1007/BF00311529.
The DNA ploidy and DNA indices (DI) of 414 patients with colorectal cancer were analyzed, and the incidence of patients with metachronous liver metastasis was found to be significantly higher in those with aneuploid tumors and a DI above 1.5 than in those with aneuploid tumors and a DI below 1.4, or in those with diploid tumors and a DI equal to 1.0. Next, to confirm the effectiveness of administering prophylactic portal infusion chemotherapy (PPIC) as adjuvant therapy for the prevention of metachronous liver metastasis in colorectal cancer, a randomized controlled trial of PPIC was performed on 110 consecutive patients with primary colorectal cancer who had undergone curative resection. Although the incidence of patients with metachronous liver metastasis in the two study groups was not significantly different at 3.3% in the PPIC group and 10.3% in the control group, the incidence in the patients with aneuploidy and a DI above 1.5 was significantly lower in the PPIC group than in the control group. These findings suggest that colorectal cancer with aneuploidy and a DI above 1.5 may have a strong tendency to metastasize to the liver, and that prophylactic portal infusion chemotherapy may be effective for preventing metachronous liver metastasis in such patients.
分析了414例结直肠癌患者的DNA倍体和DNA指数（DI），发现非整倍体肿瘤且DI高于1.5的患者异时性肝转移的发生率显著高于非整倍体肿瘤且DI低于1.4的患者，或二倍体肿瘤且DI等于1.0的患者。接下来，为了证实预防性门静脉灌注化疗（PPIC）作为辅助治疗预防结直肠癌异时性肝转移的有效性，对110例连续接受根治性切除的原发性结直肠癌患者进行了PPIC随机对照试验。虽然两个研究组中异时性肝转移患者的发生率无显著差异，PPIC组为3.3%，对照组为10.3%，但PPIC组中非整倍体且DI高于1.5的患者的发生率显著低于对照组。这些发现表明，非整倍体且DI高于1.5的结直肠癌可能有很强的肝转移倾向，预防性门静脉灌注化疗可能对预防此类患者的异时性肝转移有效。
